Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Sentinel Program Readies For Patrol As Stakeholders Watch For Details

Executive Summary

HHS unveiled the first phase of FDA's "Sentinel" post-market drug safety surveillance initiative with fanfare May 22, but stakeholders will have to wait a while for details on funding and the timing of a full-scale rollout

You may also be interested in...



Romney Advisor Leavitt Champions Part D As Model For Medicare Reform

As the presumptive architect of Republican presidential candidate Mitt Romney’s transition plan, former HHS Secretary Mike Leavitt would be a strong proponent for modeling future Medicare Parts A and B reforms on the Part D program.

Sentinel Initiative Needs Better Defined Goals, Outside Review Concludes

The Pharmacovigilance Review Subcommittee of FDA's Science Board reports a lack of clarity within CDER over just what purpose the drug safety program is supposed to serve.

FDA's Science Board To Review Comparative Effectiveness, Pharmacovigilance, Nanotech

The May 20 meeting follows a recent reorganization of the safety functions in the Center for Drug Evaluation and Research.

Related Content

UsernamePublicRestriction

Register

PS049672

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel